is a biopharmaceutical company that specializes in researching, developing and commercializing innovative medicines. The company has achieved an impressive performance, outperforming the S&P 500 by a significant 45.5 per cent. It’s the top performer of our list. Gilead Sciences generates 60 per cent of its revenue from HIV treatments, which form a resilient portion of its portfolio.
Investors are advised to do further research before investing in any of the companies listed in the accompanying table.Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: CTVNews - 🏆 1. / 99 Lire la suite »